Sugi Predict

Sugi Predict / Compounds / SCHEMBL6947700

SCHEMBL6947700

SCHEMBL6947700

COc1cc(C(C)C(=O)O)ccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 9/20 0.51
▸ AKR1C2 P52895 9/20 0.51
▸ PTGS2 P35354 6/20 0.51
▸ PTGS1 P23219 5/20 0.51
▸ SLC22A6 Q4U2R8 2/20 0.51
▸ CDC42 P60953 1/20 0.51
▸ RAC1 P63000 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ APP P05067 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ MAPT P10636 2/20 0.41
▸ CXCR1 P25024 2/20 0.41
▸ CXCR2 P25025 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ RECQL P46063 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24094531 0.85 PTGS1 (0.47) PTGS2PTGS1KCNB1ROCK2LOX
SCHEMBL30489983 0.85 LOX (0.44) APPKCNB1ROCK2LOXLOXL2
SCHEMBL30489969 0.85 PTGS1 (0.47) PTGS2PTGS1KCNB1ROCK2LOX
SCHEMBL31414450 0.83 AKR1C3 (0.43) AKR1C3AKR1C2PTGS2PTGS1SLC22A6
SCHEMBL11814403 0.82 PTGS1 (0.48) AKR1C3AKR1C2PTGS2PTGS1SLC22A6
SCHEMBL11811234 0.81 PTGS1 (0.61) AKR1C3AKR1C2PTGS2PTGS1SLC22A6
SCHEMBL29002093 0.80 AKR1C3 (0.54) AKR1C3AKR1C2PTGS2PTGS1SLC22A6
SCHEMBL24031007 0.79 PTGS2 (0.46) AKR1C3AKR1C2PTGS2PTGS1SLC22A6
SCHEMBL9366828 0.79 LOX (0.46) KCNB1ROCK2LOXLOXL2FFAR1
SCHEMBL7962904 0.79 PTGS1 (0.50) AKR1C3AKR1C2PTGS2PTGS1SLC22A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4444708-B1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2025-07-30 — — EP disclosed
US-20250129048-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2025-04-24 — — US disclosed
CN-116113635-B Spiro compounds as melanocortin 4 receptor antagonists and uses thereof 辉瑞公司 2025-03-18 — — CN disclosed
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one PFIZER INC. (US) 2025-03-13 — — US disclosed
EP-4161927-B9 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2024-11-06 — — EP disclosed
EP-4444708-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF Pfizer Inc. (US) 2024-10-16 — — EP disclosed
EP-4161927-B1 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2024-08-07 — — EP disclosed
CN-118369317-A Melanocortin 4 receptor antagonists and uses thereof 辉瑞大药厂 2024-07-19 — — CN disclosed
WO-2024059472-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-03-21 — — WO disclosed
WO-2023225661-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-11-23 — — WO disclosed
WO-2023275715-A1 METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS PFIZER INC. (US) 2023-01-05 — — WO disclosed
WO-2023275715-A1 METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS PFIZER INC. (US) 2023-01-05 — — WO disclosed
CN-115340555-A Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2022-11-15 — — CN disclosed
CN-113173924-B Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2022-07-19 — — CN disclosed
WO-2021250541-A1 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2021-12-16 — — WO disclosed
WO-2021250541-A1 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2021-12-16 — — WO disclosed
WO-2021227906-A1 PYRIDINE ACETAMIDE DERIVATIVE SERVING AS CDK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州阿尔脉生物科技有限公司 2021-11-18 — — WO disclosed
CN-113173924-A Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2021-07-27 — — CN disclosed
EP-0674623-B1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-04-09 — — EP disclosed
US-6403578-B1 ANTICOAGULANTS, CARDIOVASCULAR DISORDERS SMITHKLINE BEECHAM CORPORATION 2002-06-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one CSPP1, PRNP, RPLP2 AKR1C3 2978/4885AKR1C2 2334/4885PTGS2 2749/4885
US-20250129048-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF MC4R, MC3R, MC2R AKR1C3 468/4885AKR1C2 881/4885PTGS2 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.